US Patent 7361752 RNAi modulation of MLL-AF4 and uses thereof
Patent 7361752 was granted and assigned to Alnylam Pharmaceuticals on April, 2008 by the United States Patent and Trademark Office.
All edits
Edits on 1 Sep, 2023
Golden AI
Edits made to:
Article (+218 characters)
Article
Patent abstract
The invention relates to compositions and methods for modulating the expression of the MLL-AF4 fusion gene, and more particularly to the downregulation of MLL-AF4 by chemically modified oligonucleotides.
Edits on 13 Jul, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07361752 RNAi modulation of MLL-AF4 and uses thereof US Patent 7361752 RNAi modulation of MLL-AF4 and uses thereof
Infobox
Patent Number
0736175200
Patent Number
736175200
Edits on 25 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 4 Apr, 2023
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
073617520
Date of Patent
April 22, 2008
0Patent Application Number
113033670
Date Filed
December 14, 2005
0Official Website
Patent Primary Examiner
Edits on 24 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
073617520
Date of Patent
April 22, 2008
0Patent Application Number
113033670
Date Filed
December 14, 2005
0Official Website
Patent Primary Examiner
Edits on 17 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 25 Nov, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07361752 RNAi modulation of MLL-AF4 and uses thereof
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07361752
Date of patent
April 22, 2008
Patent application number
11303367
Date Filed
December 14, 2005
Patent primary examiner
Find more entities like US Patent 7361752 RNAi modulation of MLL-AF4 and uses thereof
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.